Buscato, Alberto N.
HRN: 01-36-84 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
04/12/2022
CO-AMOXICLAV 625MG (TAB)
04/12/2022
04/19/2022
PO
625MG
Q8
SOFT TISSUE INJURY
Waiting Final Action
Indication: Prophylaxis Type of Infection: Skin & Soft Tissue Compliance to guidelines: Guideline Not Available
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes